
Opinion|Videos|July 22, 2024
Overview of DESTINY-Breast06
Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Briefly discuss the DESTINY-Breast06, including study design, primary endpoints, and safety:
- DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
- Based on the above data, how might this impact practice patterns in HER2-low and HER2 ultra-low disease?
- Would the avail of first-line T-DXd for HER2-low and HER2 ultra-low patients influence your approach in the number of regimens of endocrine therapy you recommend to patients?
- DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.

The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5

